-
Bardot auction in Paris fetches nearly one million euros
-
Flights scrapped, evacuations urged as Typhoon Dujuan wallops Japan
-
No timeline on Daniels injury return, says Commanders coach
-
Fonseca to take break from tennis
-
British Columbia sues OpenAI in US court over Canada school shooting
-
A Cuban zoo, and its animals, in epic battle for survival
-
French star Batum retires after 18-year NBA career
-
Infantino proposes consulting federations to reform FIFA
-
Zidane leads first France training session
-
El Nino weather pattern enters record territory: scientist
-
Man shot by ICE agent in Texas detained with bullet inside him: lawyer
-
OpenAI calls for US to lead global effort on AI standards
-
California declares state of emergency ahead of El Nino
-
South African ostriches plucked alive for luxury fashion: report
-
South Africa arrests three more suspects, after nine women murdered
-
US networks halt Trump coverage in revolt over White House ban
-
Carse needs time away from England, says captain Brook
-
Paramount settles with US states to clear Warner Bros. mega-merger
-
NOWPayments Releases Cross-Chain Payout Data Revealing Key Performance Benchmarks Across TRON, BNB Chain, and Solana
-
Climate crisis a job for world leaders, not just activists: UK FM
-
British Museum bans photos of Bayeux Tapestry as crowds linger
-
US networks halt Trump coverage over White House ban
-
COP31 host says AI climate footprint to be a summit priority
-
French singer accuses Miley Cyrus of plagiarism
-
Berlin's far-left vote winners reject anti-semitism charges
-
EU fines Google 403 mn euros for location data breach
-
Mancini eager for 'new adventure' on Italy return
-
'Best is yet to come,' says De la Fuente after Spain extension
-
Mbappe says having Zidane as France coach 'like a film'
-
Why diesel prices are rising more than crude oil
-
Palmer, Rice out of England Nations League squad
-
COP31 host says AI's climate footprint to be a summit priority
-
German auto workers stage mass protests in bid to save jobs
-
Renewables hit record in 2025, but world must move faster: report
-
Embattled Merz vows to keep ruling for 'democratic future' of Germany
-
US media outlets to sue Trump administration after White House ban
-
Merz vows to keep ruling coalition together for 'democratic future' of Germany
-
Global stocks rally on lower oil prices, US-China hopes
-
Spain coach De la Fuente gets new deal after World Cup success
-
EU proposes energy rating for data centres
-
Pressure grows on Germany's Merz after election defeats
-
Schoolgirl Yu scorches to second gold as doping case rocks Games
-
China's Zhang beats Japan rivals to Asian Games gymnastics gold
-
Putin's party secures record score in Russia election
-
Samlingen Haupt: Vad pengar avslöjar om oss människor
-
Haupt Koleksiyonu: Paranın Biz İnsanlar Hakkında Anlattıkları
-
Tens of thousands of German auto workers protest to save jobs
-
Spanish PM says unregulated AI could be 'devastating'
-
हॉप्त् कलेक्शन: पैसा हमारे बारे में एक इंसान के रूप में क्या प्रकट करता है
-
Yu, 13, smashes record again with second Asian Games gold
BioEdge Research Labs Expands Independent Analytical Testing Program
US-based research peptide supplier broadens third-party analytical testing and per-batch Certificate of Analysis documentation across its research product line. All products are sold for laboratory research use only.
WILMINGTON, DE / ACCESS Newswire / September 4, 2026 / BioEdge Research Labs, a United States-based supplier of research peptides and reference materials, today announced an expansion of its independent analytical testing program. The expanded program broadens the analytical testing and batch-level documentation that accompany the company's research-use-only materials, reinforcing an approach built on verifiable, laboratory-grade documentation.
Independent analytical testing and verifiable records have become central to how laboratory and research customers evaluate research-grade materials. Rather than relying on a supplier's description alone, researchers increasingly expect documentation they can review and confirm for the specific material they receive. BioEdge's program is built around third-party analysis and a batch-specific Certificate of Analysis (COA) for every lot, giving researchers analytical records to review both before and after purchase.
Third-Party Analytical Testing
Under the expanded program, BioEdge research materials are analyzed by an independent third-party laboratory. Testing covers identity and purity by established analytical methods, including high-performance liquid chromatography (HPLC) for purity and mass spectrometry (MS) for identity confirmation, alongside contaminant screening. Reporting each result on a Certificate of Analysis tied to the specific batch allows a researcher to see the underlying analytical data, not only a summary figure.
A Certificate of Analysis for Every Lot
Each vial carries a lot number that corresponds to its own Certificate of Analysis, rather than a single certificate carried forward across multiple production runs. Because analytical results can vary from one batch to the next, per-lot documentation is what allows a researcher to match the record to the material actually in hand. Batch-specific COAs are made available on the company's product pages, and each lot number is intended to correspond to the documentation for that batch.
Documentation and Transparency
The expanded program reflects a broader emphasis on transparency in the research materials market. By centering the process on independent analysis and accessible, batch-level records, BioEdge aims to give qualified researchers a clear basis for evaluating identity, purity, and analytical documentation across the product line.
Research Use Only
All materials supplied by BioEdge Research Labs are sold strictly for laboratory research and in vitro use by qualified researchers and scientific professionals. They are not drugs, supplements, or medical products.
About BioEdge Research Labs
BioEdge Research Labs is a United States-based supplier of research peptides and reference materials serving laboratory and research customers. The company provides research-grade materials supported by independent third-party analytical testing and batch-specific Certificates of Analysis. Learn more at https://thebioedgeresearchlabs.com.
Media Contact
1842 Marketstone Avenue, Suite 410
Wilmington, DE 19801
(302) 757-0147
[email protected]
All products sold by BioEdge Research Labs are intended strictly for laboratory research and in vitro use by qualified researchers and scientific professionals. These products are not intended to diagnose, treat, cure, or prevent any disease, are not intended to affect the structure or any function of the body, and are not intended for human or veterinary use, consumption, or self-administration. They have not been evaluated or approved by the U.S. Food and Drug Administration for diagnostic, therapeutic, or preventative purposes. BioEdge Research Labs is a chemical supplier and is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. BioEdge Research Labs makes no therapeutic claims.
SOURCE: The BioEdge Research Labs
View the original press release on ACCESS Newswire
O.Norris--AMWN